Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials.
about
Second-Line Treatment of NSCLC-The Pan-ErbB Inhibitor Afatinib in Times of Shifting Paradigms.A Neuro-oncologist's Perspective on Management of Brain Metastases in Patients with EGFR Mutant Non-small Cell Lung Cancer.Novel EGFR Inhibitors in Non-small Cell Lung Cancer: Current Status of Afatinib.Afatinib: A Review in Advanced Non-Small Cell Lung Cancer.Lung cancer requires multidisciplinary treatment to improve patient survival: A case report.EGFR TKI as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer.Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma.Afatinib Therapy for Brain Metastases Aggravated by a Reduction in the Dose of Erlotinib Due to the Development of Hepatotoxicity.The efficacy of 40 mg versus dose de-escalation to less than 40 mg of afatinib (Giotrif) as the first-line therapy for patients with primary lung adenocarcinoma harboring favorable epidermal growth factor mutations.The clinical efficacy of Afatinib 30 mg daily as starting dose may not be inferior to Afatinib 40 mg daily in patients with stage IV lung Adenocarcinoma harboring exon 19 or exon 21 mutations.Detection of Rare Mutations in EGFR-ARMS-PCR-Negative Lung Adenocarcinoma by Sanger Sequencing.The Effectiveness of Afatinib in a Patient with Advanced Lung Adenocarcinoma Harboring Rare G719X and S768I Mutations.Optimizing outcomes in EGFR mutation-positive NSCLC: which tyrosine kinase inhibitor and when?Turning EGFR mutation-positive non-small-cell lung cancer into a chronic disease: optimal sequential therapy with EGFR tyrosine kinase inhibitors.Case series on the association between blood levels and side effects of afatinib maleate.Afatinib in advanced NSCLC: a profile of its use.First-Line Treatment in EGFR Mutant Non-Small Cell Lung Cancer: Is There a Best Option?Comparison of the effects of the three major tyrosine kinase inhibitors as first-line therapy for non-small-cell lung cancer harboring epidermal growth factor receptor mutations.
P2860
Q37637905-A55FE3A3-6242-4FA4-908F-0462559E4BE6Q37742623-E4718C16-D736-4AE9-B3FF-BED743FBC0C9Q38990576-7CA3CAE2-0A48-4366-ADB9-9BFE5755DA5CQ39016290-1BE61B3A-4466-4489-995D-DCBE248A10DCQ41597415-540DB74A-F140-4336-BDF2-B8AA1F551198Q45886897-C4CE6D7D-4DB8-47F2-B923-FFF4622A525EQ47102256-32229FB2-840E-4437-91AC-C772DC782AEAQ47133946-466BE78B-AA29-4978-9AE7-437B3AF9A639Q47138128-8D03972E-851F-483D-9EA5-132C4E522974Q47193937-4522482F-2D60-42DC-B489-0836513E07DFQ47198852-B019A03C-703C-4F26-9A88-8E402DEDF595Q47684854-153F92C5-B74B-466E-B572-9F9A8AE745BEQ47730834-966685BB-69C8-45F7-9DCC-54314DA28E66Q49300205-223CF56D-0300-4942-AAE0-A58694D385E9Q51825102-5579DCDB-9A2B-4C6B-8BE9-CB58201E00A9Q52655265-59D847B6-61F4-4DF2-B510-55BD62BBE42FQ54110124-313361E7-C716-4E2E-8189-663A70A6D37FQ54941379-8F452F55-4583-44BE-8877-04758D3E292D
P2860
Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Effect of dose adjustment on t ...... mized LUX-Lung 3 and 6 trials.
@en
type
label
Effect of dose adjustment on t ...... mized LUX-Lung 3 and 6 trials.
@en
prefLabel
Effect of dose adjustment on t ...... mized LUX-Lung 3 and 6 trials.
@en
P2093
P2860
P356
P1433
P1476
Effect of dose adjustment on t ...... omized LUX-Lung 3 and 6 trials
@en
P2093
J C-H Yang
L V Sequist
P2860
P304
P356
10.1093/ANNONC/MDW322
P50
P577
2016-09-06T00:00:00Z